Host: The Japanese Pharmacological Society
Name : The 97th Annual Meeting of the Japanese Pharmacological Society
Number : 97
Location : [in Japanese]
Date : December 14, 2023 - December 16, 2023
The COVID-19 pandemic has changed how we live, work, learn, and interact in less than a year since the virus emerged. This also changed the way of virus research more translational. One of major contributors is air-liquid interface (ALI) cultured airway epithelium, ready-made or user-friendly construction kits. There are a lot of evidence of the limitation of the virus work using cancer cell lines, submerged monolayer culture or human respiratory virus semi-permissive animals. ALI airway epithelium, which closely mimic human airway epithelium morphologically or physiologically, are infected well with human respiratory viruses including influenza and coronavirus. Antiviral test of new compounds in this model would provide the best proof-of-concept (PoC) and help to build confidence for further clinical development. However, this system is more useful for industry than we thought. This system can be used to determine dosing regimen (prophylaxis, therapeutic etc) due to a long shelf life, clinical dose prediction, effective clinical parameter prediction, dosing route decision, power calculation for clinical trials, PK-PD relationship, prediction of inhaled toxicity and to test in disease population. Most importantly, as the use of system consequently reduces animal study, this contributes to 3Rs concept, which is very important for future drug discovery. Thus, ALI airway epithelium is not only a biology system simply to evaluate virus replication or a PoC, but also can be used for preclinical drug development broadly for industry.
